These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33849967)

  • 1. Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?
    Biltaji E; Walker B; Au TH; Rivers Z; Ose J; Li CI; Brixner DI; Stenehjem DD; Ulrich CM
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1106-1113. PubMed ID: 33849967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
    Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
    Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.
    Hassan C; Rex DK; Cooper GS; Zullo A; Launois R; Benamouzig R
    Gut; 2012 Aug; 61(8):1172-9. PubMed ID: 21997545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses.
    Pence BC; Belasco EJ; Lyford CP
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):399-405. PubMed ID: 23250933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Jiang M; You JHS
    Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer.
    Squires H; Tappenden P; Cooper K; Carroll C; Logan R; Hind D
    Clin Ther; 2011 Sep; 33(9):1289-305. PubMed ID: 21840057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
    Okere AN; Ezendu K; Berthe A; Diaby V
    J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis.
    Suleiman S; Rex DK; Sonnenberg A
    Gastroenterology; 2002 Jan; 122(1):78-84. PubMed ID: 11781283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
    Lala A; Berger JS; Sharma G; Hochman JS; Scott Braithwaite R; Ladapo JA
    J Thromb Haemost; 2013 Jan; 11(1):81-91. PubMed ID: 23137413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV; Wolff R; Ramaekers BLT; Van Giessen A; Lang S; Ryder S; Worthy G; Duffy S; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
    Hur C; Simon LS; Gazelle GS
    Cancer; 2004 Jul; 101(1):189-97. PubMed ID: 15222006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Unim B; Pitini E; De Vito C; D'Andrea E; Marzuillo C; Villari P
    Value Health; 2020 Jan; 23(1):114-126. PubMed ID: 31952666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.